
Global mRNA Platform Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global mRNA Platform market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the mRNA Platform market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the mRNA Platform market include Arcturus Therapeutic, Argos Therapeutics, BioNTec, CureVac, Etherna, Ethris, Translate Bio, GlaxoSmithKline and Pfizer, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for mRNA Platform, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Platform, also provides the value of main regions and countries. Of the upcoming market potential for mRNA Platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Platform revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global mRNA Platform company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
mRNA Platform Segment by Company
Arcturus Therapeutic
Argos Therapeutics
BioNTec
CureVac
Etherna
Ethris
Translate Bio
GlaxoSmithKline
Pfizer
mRNA Platform Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Platform Segment by Application
Infectious Disease
Cancer
mRNA Platform Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global mRNA Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the mRNA Platform key companies, revenue, market share, and recent developments.
3. To split the mRNA Platform breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions mRNA Platform market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify mRNA Platform significant trends, drivers, influence factors in global and regions.
6. To analyze mRNA Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Platform industry.
Chapter 3: Detailed analysis of mRNA Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of mRNA Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of mRNA Platform in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
According to APO Research, the global mRNA Platform market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the mRNA Platform market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for mRNA Platform is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the mRNA Platform market include Arcturus Therapeutic, Argos Therapeutics, BioNTec, CureVac, Etherna, Ethris, Translate Bio, GlaxoSmithKline and Pfizer, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for mRNA Platform, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Platform, also provides the value of main regions and countries. Of the upcoming market potential for mRNA Platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Platform revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global mRNA Platform company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
mRNA Platform Segment by Company
Arcturus Therapeutic
Argos Therapeutics
BioNTec
CureVac
Etherna
Ethris
Translate Bio
GlaxoSmithKline
Pfizer
mRNA Platform Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Platform Segment by Application
Infectious Disease
Cancer
mRNA Platform Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global mRNA Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the mRNA Platform key companies, revenue, market share, and recent developments.
3. To split the mRNA Platform breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions mRNA Platform market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify mRNA Platform significant trends, drivers, influence factors in global and regions.
6. To analyze mRNA Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Platform industry.
Chapter 3: Detailed analysis of mRNA Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of mRNA Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of mRNA Platform in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global mRNA Platform Market Size, 2020 VS 2024 VS 2031
- 1.3 Global mRNA Platform Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 mRNA Platform Market Dynamics
- 2.1 mRNA Platform Industry Trends
- 2.2 mRNA Platform Industry Drivers
- 2.3 mRNA Platform Industry Opportunities and Challenges
- 2.4 mRNA Platform Industry Restraints
- 3 mRNA Platform Market by Company
- 3.1 Global mRNA Platform Company Revenue Ranking in 2024
- 3.2 Global mRNA Platform Revenue by Company (2020-2025)
- 3.3 Global mRNA Platform Company Ranking (2023-2025)
- 3.4 Global mRNA Platform Company Manufacturing Base and Headquarters
- 3.5 Global mRNA Platform Company Product Type and Application
- 3.6 Global mRNA Platform Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global mRNA Platform Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 mRNA Platform Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 mRNA Platform Market by Type
- 4.1 mRNA Platform Type Introduction
- 4.1.1 Infectious Disease Vaccines
- 4.1.2 Cancer Vaccines
- 4.2 Global mRNA Platform Sales Value by Type
- 4.2.1 Global mRNA Platform Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global mRNA Platform Sales Value by Type (2020-2031)
- 4.2.3 Global mRNA Platform Sales Value Share by Type (2020-2031)
- 5 mRNA Platform Market by Application
- 5.1 mRNA Platform Application Introduction
- 5.1.1 Infectious Disease
- 5.1.2 Cancer
- 5.2 Global mRNA Platform Sales Value by Application
- 5.2.1 Global mRNA Platform Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global mRNA Platform Sales Value by Application (2020-2031)
- 5.2.3 Global mRNA Platform Sales Value Share by Application (2020-2031)
- 6 mRNA Platform Regional Value Analysis
- 6.1 Global mRNA Platform Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global mRNA Platform Sales Value by Region (2020-2031)
- 6.2.1 Global mRNA Platform Sales Value by Region: 2020-2025
- 6.2.2 Global mRNA Platform Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America mRNA Platform Sales Value (2020-2031)
- 6.3.2 North America mRNA Platform Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe mRNA Platform Sales Value (2020-2031)
- 6.4.2 Europe mRNA Platform Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific mRNA Platform Sales Value (2020-2031)
- 6.5.2 Asia-Pacific mRNA Platform Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America mRNA Platform Sales Value (2020-2031)
- 6.6.2 South America mRNA Platform Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa mRNA Platform Sales Value (2020-2031)
- 6.7.2 Middle East & Africa mRNA Platform Sales Value Share by Country, 2024 VS 2031
- 7 mRNA Platform Country-level Value Analysis
- 7.1 Global mRNA Platform Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global mRNA Platform Sales Value by Country (2020-2031)
- 7.2.1 Global mRNA Platform Sales Value by Country (2020-2025)
- 7.2.2 Global mRNA Platform Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.3.2 USA mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.7.2 France mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.14.2 China mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.17.2 India mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt mRNA Platform Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt mRNA Platform Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt mRNA Platform Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Arcturus Therapeutic
- 8.1.1 Arcturus Therapeutic Comapny Information
- 8.1.2 Arcturus Therapeutic Business Overview
- 8.1.3 Arcturus Therapeutic mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.1.4 Arcturus Therapeutic mRNA Platform Product Portfolio
- 8.1.5 Arcturus Therapeutic Recent Developments
- 8.2 Argos Therapeutics
- 8.2.1 Argos Therapeutics Comapny Information
- 8.2.2 Argos Therapeutics Business Overview
- 8.2.3 Argos Therapeutics mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.2.4 Argos Therapeutics mRNA Platform Product Portfolio
- 8.2.5 Argos Therapeutics Recent Developments
- 8.3 BioNTec
- 8.3.1 BioNTec Comapny Information
- 8.3.2 BioNTec Business Overview
- 8.3.3 BioNTec mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.3.4 BioNTec mRNA Platform Product Portfolio
- 8.3.5 BioNTec Recent Developments
- 8.4 CureVac
- 8.4.1 CureVac Comapny Information
- 8.4.2 CureVac Business Overview
- 8.4.3 CureVac mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.4.4 CureVac mRNA Platform Product Portfolio
- 8.4.5 CureVac Recent Developments
- 8.5 Etherna
- 8.5.1 Etherna Comapny Information
- 8.5.2 Etherna Business Overview
- 8.5.3 Etherna mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.5.4 Etherna mRNA Platform Product Portfolio
- 8.5.5 Etherna Recent Developments
- 8.6 Ethris
- 8.6.1 Ethris Comapny Information
- 8.6.2 Ethris Business Overview
- 8.6.3 Ethris mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.6.4 Ethris mRNA Platform Product Portfolio
- 8.6.5 Ethris Recent Developments
- 8.7 Translate Bio
- 8.7.1 Translate Bio Comapny Information
- 8.7.2 Translate Bio Business Overview
- 8.7.3 Translate Bio mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.7.4 Translate Bio mRNA Platform Product Portfolio
- 8.7.5 Translate Bio Recent Developments
- 8.8 GlaxoSmithKline
- 8.8.1 GlaxoSmithKline Comapny Information
- 8.8.2 GlaxoSmithKline Business Overview
- 8.8.3 GlaxoSmithKline mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.8.4 GlaxoSmithKline mRNA Platform Product Portfolio
- 8.8.5 GlaxoSmithKline Recent Developments
- 8.9 Pfizer
- 8.9.1 Pfizer Comapny Information
- 8.9.2 Pfizer Business Overview
- 8.9.3 Pfizer mRNA Platform Revenue and Gross Margin (2020-2025)
- 8.9.4 Pfizer mRNA Platform Product Portfolio
- 8.9.5 Pfizer Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.